Sensei Biotherapeutics, Inc. (NASDAQ:SNSE) Short Interest Update

Sensei Biotherapeutics, Inc. (NASDAQ:SNSE) saw a significant decline in short interest during the month of March. As of March 15th, there was short interest totalling 121,000 shares, a decline of 17.5% from the February 28th total of 146,700 shares. Based on an average daily trading volume, of 322,600 shares, the short-interest ratio is presently 0.4 days. Currently, 0.7% of the shares of the company are sold short.

Sensei Biotherapeutics Price Performance

Shares of SNSE traded down $0.01 during midday trading on Wednesday, reaching $0.34. The stock had a trading volume of 279,742 shares, compared to its average volume of 911,690. The company has a market capitalization of $8.48 million, a P/E ratio of -0.28 and a beta of 0.16. The firm’s 50 day moving average price is $0.46 and its 200-day moving average price is $0.49. Sensei Biotherapeutics has a 52 week low of $0.25 and a 52 week high of $1.94.

Sensei Biotherapeutics (NASDAQ:SNSE) last issued its quarterly earnings results on Friday, March 28th. The company reported ($0.27) EPS for the quarter, hitting the consensus estimate of ($0.27). On average, equities analysts forecast that Sensei Biotherapeutics will post -1.17 earnings per share for the current year.

Institutional Trading of Sensei Biotherapeutics

An institutional investor recently raised its position in Sensei Biotherapeutics stock. XTX Topco Ltd lifted its stake in shares of Sensei Biotherapeutics, Inc. (NASDAQ:SNSE) by 351.7% in the 4th quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The institutional investor owned 62,903 shares of the company’s stock after acquiring an additional 48,977 shares during the quarter. XTX Topco Ltd owned 0.25% of Sensei Biotherapeutics worth $31,000 at the end of the most recent reporting period. Institutional investors own 10.50% of the company’s stock.

Analyst Upgrades and Downgrades

A number of brokerages recently issued reports on SNSE. HC Wainwright reissued a “buy” rating and issued a $4.00 price objective on shares of Sensei Biotherapeutics in a report on Friday, March 28th. Oppenheimer raised their price target on Sensei Biotherapeutics from $3.50 to $4.00 and gave the company an “outperform” rating in a report on Friday, March 28th.

Sensei Biotherapeutics Company Profile

Sensei Biotherapeutics, Inc, an immuno-oncology company, engages in the discovery and development of therapeutics for cancer patients. The company's Tumor Microenvironment Activated Biologics platform is designed to generate highly selective therapeutics that disable immunosuppressive signals or activate immunostimulatory signals selectively in the tumor microenvironment.